“Interestingly, BIRC5 and MCL-1 have both been reported to be over-expressed and strongly correlated with progression and ...

The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent BTK inhibitors with fewer adverse events in mantle cell lymphoma.

Mantle cell lymphoma (MCL) is often an aggressive form of cancer traditionally treated with chemotherapy, immunotherapy, and stem cell transplants when appropriate. Emerging therapies may offer more ...

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades. Treatment — ...

Research offers promising insights into the ideal frontline therapies for mantle cell lymphoma (MCL), but there are continued unmet needs in the relapsed/refractory setting, blood cancer specialists ...

With three BTK inhibitors approved for treatment of mantle cell lymphoma, patients and providers should consider side effects and insurance coverage before deciding on a drug. Bruton tyrosine kinase ...

We enrolled 50 patients with MCL in this single-institution, single-arm, phase II clinical trial (NCT01880567). Patients with Ki-67% ≥ 50% and blastoid morphology were excluded. Ibrutinib was ...

Please provide your email address to receive an email when new articles are posted on . Early in my career, I treated grade 3 MCL injuries in conjunction with ACL tears with early surgery and suture ...